Registry of Lobbyists
Total Number of Communication Reports: 0
Monthly communication reports in the last 6 months: 0
The corporation is the U.S. based subsidiary of VBI Vaccines Inc., a commercial-stage, biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. Through its Canadian subsidiary, Variation Biotechnologies Inc., located in Ottawa, Ontario, it is developing a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (“SARS”), and Middle East respiratory syndrome (“MERS”) based on its virus-like particle (“eVLP”) platform technology which closely mimics the structure of the target virus to elicit a potent immune response. It is also developing vaccine candidates for treatment of glioblastoma multiforme (“GBM”), for prevention of cytomegalovirus and, in collaboration with Brii Biosciences Limited, an immunotherapeutic vaccine for treatment of chronic hepatitis B. Through the corporation’s Israeli subsidiary, SciVac Limited, it manufactures a tri-antigenic hepatitis B vaccine, Sci-B-Vac, which is approved for use and commercially available in Israel, and has completed a Phase III program in the United States, Europe and Canada.
Jeffrey Baxter, Chief Executive Officer
End date of the last completed financial year: 2019-12-31
| Government Institution | Funding Received in Last Financial Year | Funding Expected in Current Financial Year |
|---|---|---|
| Innovation, Science and Economic Development Canada (ISED) | $0.00 | Yes |
| National Research Council (NRC) | $0.00 | Yes |
Address:
2241-222 Third Street
Cambridge, MA 02142
United States of America
Telephone number:
617-830-3031